Physician profile
Scott W Craven
NPI 1457863839
$3,671.09
in general payments reported to CMS, 2019-2025
23 companies · $1,967 in 2025
The $1,967 reported for 2025 was more than what 93% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $307 · 2024: $1,397 · 2025: $1,967.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,345 · Education: $326.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,345.46 |
| Education | $325.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $690.20 | 2023-2025 | Tremfya |
| Abbvie INC. | $573.39 | 2023-2025 | |
| Genzyme Corporation | $382.21 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $340.34 | 2023-2025 | Dupixent |
| Galderma Laboratories, L.P. | $290.89 | 2025 | Nemluvio |
| Sun Pharmaceutical Industries INC. | $231.31 | 2023-2025 | Ilumya |
| Merz North America, INC. | $149.96 | 2025 | |
| Ucb, INC. | $140.12 | 2025 | Bimzelx |
| Amgen INC. | $129.24 | 2023-2025 | Otezla, Otezla |
| Lilly USA, LLC | $119.61 | 2023-2025 | Ebglyss, Taltz, Olumiant |
| Pfizer INC. | $113.56 | 2023-2024 | |
| Sanofi-Aventis U.S. LLC | $99.99 | 2024 | |
| Mayne Pharma Commercial LLC | $73.21 | 2025 | |
| Organon LLC | $50.14 | 2025 | Vtama |
| Novartis Pharmaceuticals Corporation | $44.73 | 2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.46 | 2023-2024 | Spevigo |
| Arcutis Biotherapeutics, INC. | $42.69 | 2025 | Zoryve |
| Almirall LLC | $40.12 | 2024 | Klisyri |
| Incyte Corporation | $28.00 | 2025 | Opzelura |
| Verrica Pharmaceuticals INC. | $27.79 | 2024 | Ycanth |
| Helsinn Therapeutics (U.S.), INC. | $20.84 | 2025 | Valchlor |
| Dermavant Sciences, INC. | $19.44 | 2024 | Vtama |
| Leo Pharma INC. | $18.85 | 2025 | Adbry |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Craven listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.